Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-1439 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TD-1439 | EXPERIMENTAL | Capsule formulation |
| Placebo | PLACEBO_COMPARATOR | Capsule formulation |
| Name | Type | Description |
|---|---|---|
| TD-1439 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Body Mass Index (BMI) 18 to 32 kg/m2 inclusive * Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use highly effective methods of birth control * Women of non-childbearing potential are at least 2 years postmenopausal or are s...
TD-1439 is an investigational small molecule being developed by Theravance Biopharma, Inc. (TBPH). It has been studied in Phase 1 clinical trials in healthy subjects, including healthy adults and elderly subjects. The drug is not approved and remains in clinical development.
TD-1439 has been studied in healthy volunteers, including healthy adults and elderly subjects, in early-stage clinical trials. Its intended therapeutic use has not been established, as it is still in Phase 1 development.
TD-1439 is being developed by Theravance Biopharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TBPH. The company has conducted Phase 1 studies of this investigational small molecule in the United States.
TD-1439 is in Phase 1 clinical development. Two Phase 1 trials have been completed, including a single ascending dose study and a multiple ascending dose study in healthy subjects. The drug is investigational and has not been approved.
TD-1439 has been studied in two completed Phase 1 trials. NCT02903095 was a single ascending dose study in healthy subjects with 66 participants. NCT02954263 was a multiple ascending dose study in healthy adult and elderly subjects with 40 participants. Both were conducted in the United States.
TD-1439 is the sole name provided for this investigational drug. No alternative names have been identified in the available clinical trial information.